durvalumab,paclitaxel,carboplatin,cisplatin,gemcitabine,pemetrexed
astrazeneca
['durva', 'aegean']
the #oncoalerttoptweet day 3 #aacr23 tweet by our faculty interim analysis of efs from aegean shows durvalumab pre/post surgery significantly improves pfs (hr 0.68) over placebo with 1y efs rate 73.4% vs 64.5% and 2y efs rate 63.3% vs 52.4% 
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨